ES2483720T3 - Un polipéptido de hemolisina alfa recombinante de Staphylococcus aureus, que tiene una deleción en el dominio del tallo y secuencias heterólogas insertadas - Google Patents

Un polipéptido de hemolisina alfa recombinante de Staphylococcus aureus, que tiene una deleción en el dominio del tallo y secuencias heterólogas insertadas Download PDF

Info

Publication number
ES2483720T3
ES2483720T3 ES10700742.9T ES10700742T ES2483720T3 ES 2483720 T3 ES2483720 T3 ES 2483720T3 ES 10700742 T ES10700742 T ES 10700742T ES 2483720 T3 ES2483720 T3 ES 2483720T3
Authority
ES
Spain
Prior art keywords
amino acid
protein
acid position
icha
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10700742.9T
Other languages
English (en)
Spanish (es)
Inventor
Patrice Filée
Noureddine Rhazi
Moreno Galleni
Bernard Taminiau
Olivier Jolois
Alfred Collard
Alain Jacquet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CT D ECONOMIE RURALE
University of Liège
Université Libre de Bruxelles
Centre d'Economie Rurale
Original Assignee
CT D ECONOMIE RURALE
University of Liège
Université Libre de Bruxelles
Centre d'Economie Rurale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CT D ECONOMIE RURALE, University of Liège, Université Libre de Bruxelles, Centre d'Economie Rurale filed Critical CT D ECONOMIE RURALE
Application granted granted Critical
Publication of ES2483720T3 publication Critical patent/ES2483720T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES10700742.9T 2009-01-19 2010-01-15 Un polipéptido de hemolisina alfa recombinante de Staphylococcus aureus, que tiene una deleción en el dominio del tallo y secuencias heterólogas insertadas Active ES2483720T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09150888 2009-01-19
EP09150888A EP2208787A1 (en) 2009-01-19 2009-01-19 A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
PCT/EP2010/050453 WO2010081875A1 (en) 2009-01-19 2010-01-15 A recombinant alpha-hemolysin polypeptide of staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted

Publications (1)

Publication Number Publication Date
ES2483720T3 true ES2483720T3 (es) 2014-08-07

Family

ID=40811673

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10700742.9T Active ES2483720T3 (es) 2009-01-19 2010-01-15 Un polipéptido de hemolisina alfa recombinante de Staphylococcus aureus, que tiene una deleción en el dominio del tallo y secuencias heterólogas insertadas

Country Status (7)

Country Link
US (1) US8545853B2 (enExample)
EP (2) EP2208787A1 (enExample)
JP (1) JP5781941B2 (enExample)
AU (1) AU2010205645B2 (enExample)
CA (1) CA2749862C (enExample)
ES (1) ES2483720T3 (enExample)
WO (1) WO2010081875A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2419129A2 (en) 2009-04-14 2012-02-22 Novartis AG Compositions for immunising against staphylococcus aerus
RS58190B2 (sr) * 2011-02-08 2021-08-31 Medimmune Llc Antitela koja specifično vezuju staphylococcus aureus alfa toksin i postupci njihove primene
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
RU2632651C2 (ru) * 2011-05-11 2017-10-06 Чилдрен'С Медикал Сентер Корпорейшн Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
WO2012178093A1 (en) 2011-06-24 2012-12-27 Electronic Biosciences Inc. High contrast signal to noise ratio device components
CN102977214B (zh) * 2012-09-29 2014-03-12 重庆原伦生物科技有限公司 用于耐甲氧西林金黄色葡萄球菌（mrsa）疫苗的重组蛋白hf2及制备方法和应用
US10047129B2 (en) 2012-12-20 2018-08-14 Electronic Biosciences, Inc. Modified alpha hemolysin polypeptides and methods of use
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
MX377794B (es) * 2014-03-26 2025-03-10 Glaxosmithkline Biologicals Sa Antigenos estafilococicos mutantes.
KR101964619B1 (ko) * 2014-09-29 2019-04-02 후지필름 가부시키가이샤 항체 결합성 폴리펩타이드, 항체 결합성 융합 폴리펩타이드 및 흡착 재료
CN105641689B (zh) * 2016-01-21 2024-09-10 浙江海隆生物科技股份有限公司 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用
US11414464B2 (en) 2016-07-22 2022-08-16 Evaxion Biotech A/S Chimeric proteins for inducing immunity towards infection with S. aureus
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGENIC COMPOSITION AND USES THEREOF
SG11201912601RA (en) 2017-06-23 2020-01-30 Nosocomial Vaccine Corp Immunogenic compositions
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
CN113164580B (zh) 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗
MX2021004173A (es) 2018-10-09 2021-09-08 Medimmune Llc Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.
WO2024168197A2 (en) * 2023-02-08 2024-08-15 The Regents Of The University Of California Membrane translocation compositions and methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999005167A1 (en) * 1997-07-25 1999-02-04 University Of Massachusetts Designed protein pores as components for biosensors
ES2321892T3 (es) 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
AU2001292674A1 (en) * 2000-09-15 2002-04-29 University Of Connecticut Health Center Improved formulations using heat shock/stress protein-peptide complexes
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CN1674933B (zh) * 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
ES2730275T3 (es) * 2004-09-22 2019-11-11 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
JP2009539979A (ja) 2006-06-12 2009-11-19 ナビ バイオファーマシューティカルズ ブドウ球菌感染症を治療および予防するための、α毒素の使用

Also Published As

Publication number Publication date
EP2382316A1 (en) 2011-11-02
EP2208787A1 (en) 2010-07-21
EP2382316B1 (en) 2014-04-23
CA2749862C (en) 2015-02-24
US20120014983A1 (en) 2012-01-19
AU2010205645A1 (en) 2011-07-14
WO2010081875A1 (en) 2010-07-22
AU2010205645B2 (en) 2014-09-04
JP5781941B2 (ja) 2015-09-24
CA2749862A1 (en) 2010-07-22
US8545853B2 (en) 2013-10-01
JP2013504301A (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
CA2749862C (en) A recombinant alpha-hemolysin polypeptide of staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
Fattahian et al. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap)
CN103906535B (zh) 与葡萄球菌蛋白a的抗体相关的组合物和方法
KR101505496B1 (ko) 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물
CA2655133C (en) Use of alpha-toxin for treating and preventing staphylococcus infections
DK2668208T3 (en) The cross-reactive antibody Staphylococcus Aureus
US20180179267A1 (en) Anti-staphylococcus aureus antibody combination preparation
ES2625979T3 (es) Tratamiento de infecciones
AU2006257774B2 (en) Use of Panton-Valentine Leukocidin for treating and preventing Staphylococcus infections
Haghighat et al. Recombinant PBP2a as a vaccine candidate against methicillin-resistant Staphylococcus aureus: immunogenicity and protectivity
EP1987836B1 (en) Protective staphylococcus aureus vaccine based on cell wall-associated proteins
US20150165015A1 (en) Use of alpha-toxin for treating and preventing staphylococcus infections
CA3155424A1 (en) Staphylococcus peptides and methods of use
CN115720521A (zh) 用于预防金黄色葡萄球菌感染的组合物和方法
KR20170137111A (ko) 에스. 아우레우스의 면역글로불린 결합 단백질에 대해 지시된 항체
WO2018093822A1 (en) Chimeric antibodies comprising binding domains of phage lysins, bacterial autolysins, bacteriocins, and phage tail or tail fibers
HK40101755A (en) Novel composition for prevention or treatment of staphylococcus aureus infectious disease
WO2008127102A1 (en) S. pnuemoniae transcytosis protein
HK1243089A1 (en) Immunogenic pcpa polypeptides and uses thereof
HK1197654B (en) Compositions and methods related to antibodies to staphylococcal protein a